Delaware Health News Online: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.

June 2026

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

July 2026

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

August 2026

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Press releases published on June 9, 2026

Jun. 9, 2026

ARCPOINT ANNOUNCES APPOINTMENT OF PETER KENDALL AS INTERIM CHIEF EXECUTIVE OFFICER

GlobeNewswire

Jun. 9, 2026

BETMAT Quantitative Endotoxin Analysis System for Enhanced Testing Precision

EIN Presswire

Jun. 9, 2026

How Does BETMAT RCR Assay Support the Transition from LAL to Recombinant Endotoxin Testing in BET Solutions

EIN Presswire

Jun. 9, 2026

Can BETMAT Sustainable rFC Endotoxin Testing Improve Parenteral Drug Quality Control

EIN Presswire

Jun. 9, 2026

Technical Guide: Implementing Kinetic Chromogenic LAL Reagent for Quantitative BET Applications in Pharmaceutical QC

EIN Presswire

Jun. 9, 2026

Enhance Quality Control with BETMAT’s Kinetic Chromogenic LAL Reagent for Quantitative BET Applications

EIN Presswire

Jun. 9, 2026

TerrAscend Announces Results of Annual General Meeting

GlobeNewswire

Jun. 9, 2026

BETMAT Kinetic Turbidimetric Assay (KTA) Safeguards Pharmaceutical Endotoxin Testing with Reliable Advanced Detection

EIN Presswire

Jun. 9, 2026

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

GlobeNewswire

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

Jun. 9, 2026